Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding Ltd (OP: RHHBF ) 292.10 +1.76 (+0.61%) Streaming Delayed Price Updated: 9:45 AM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 4 Open 290.34 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 290.34 Today's Range 292.10 - 292.10 52wk Range 243.42 - 347.50 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report April 09, 2024 Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools. Via Benzinga Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M January 02, 2024 Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. Via Benzinga Exposures COVID-19 Performance YTD -4.90% -4.90% 1 Month +1.55% +1.55% 3 Month +10.64% +10.64% 6 Month -9.57% -9.57% 1 Year -9.29% -9.29% More News Read More Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial December 11, 2023 Via Benzinga Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation December 05, 2023 Via Benzinga Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs December 04, 2023 Via Benzinga Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks October 31, 2023 Via Benzinga Exposures Product Safety Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal October 23, 2023 Via Benzinga Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products October 19, 2023 Via Benzinga Exposures COVID-19 What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? October 17, 2023 Via Benzinga Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready October 11, 2023 Via Benzinga Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares October 04, 2023 Via Benzinga Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges September 27, 2023 Via Benzinga Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year September 21, 2023 Via Benzinga Exposures COVID-19 Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope September 07, 2023 Via Benzinga Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer September 01, 2023 Via Benzinga Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time August 30, 2023 Via Benzinga Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update August 23, 2023 Via Benzinga Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study August 23, 2023 Via Benzinga Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Via Benzinga Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations July 28, 2023 Via Benzinga Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List July 26, 2023 Via Benzinga Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy July 24, 2023 Via Benzinga Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal July 14, 2023 Via Benzinga Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion July 13, 2023 Via Benzinga Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma June 16, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
